Last $2.24 USD
Change Today -0.01 / -0.44%
Volume 644.0K
NURO On Other Exchanges
NURO is not on other exchanges.
As of 8:10 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

neurometrix inc (NURO) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/10/13 - $4.25
52 Week Low
10/28/13 - $1.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEUROMETRIX INC (NURO)

Related News

No related news articles were found.

neurometrix inc (NURO) Related Businessweek News

No Related Businessweek News Found

neurometrix inc (NURO) Details

NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with carpal tunnel syndrome, lumbosacral disc disease, spinal stenosis, and diabetes. The company focuses on the diagnosis and treatment of neurological complications of diabetes. Its marketed products include SENSUS pain therapy device, a transcutaneous electrical nerve stimulator used for chronic and intractable pain, such as painful diabetic neuropathy; NC-stat DPNCheck, a device used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy (DPN); and ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies and invasive electromyography procedures for the assessment of carpal tunnel syndrome, low back and leg pain, and DPN, as well as consumables and accessories. The company distributes its products through its direct sales force and independent sales representatives to physicians, clinics, hospitals, managed care organizations, retail health businesses, and independent distributors consisting of primary care, internal medicine, orthopedic and hand surgeons, pain medicine physicians, neurologists, physical medicine and rehabilitation, physicians, and neurosurgeons, as well as endocrinology and podiatry markets primarily in the United States, Europe, Asia, and the Middle East. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.

30 Employees
Last Reported Date: 02/24/14
Founded in 1996

neurometrix inc (NURO) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $436.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $311.3K
Senior Vice President of Information Technolo...
Total Annual Compensation: $263.2K
Compensation as of Fiscal Year 2013.

neurometrix inc (NURO) Key Developments

FDA Clears NeuroMetrix Wearable Technology for Over-the-Counter Use in Treatment of Chronic Pain

NeuroMetrix Inc. announced that its wearable technology for treatment of chronic pain received 510(k) clearance (K140333) from the U.S. Food and Drug Administration (FDA) for over-the-counter use. The company is in late stage development of a consumer oriented chronic pain treatment product. The device is based on wearable technology, presently deployed in the company's SENSUS(R) Pain Management System, that utilizes comfortable, non-invasive electrical stimulation of sensory nerves to induce safe and effective pain relief. It is lightweight and can be worn during the day while active, and at night while sleeping. This 510(k) clearance allows the Company to market the over-the-counter device through retail distribution channels without a prescription requirement.

Michael Williams Resigns as Senior Vice President of Engineering and Chief Technology Officer of NeuroMetrix Inc

On June 23, 2014, Michael Williams resigned from his position as Senior Vice President of Engineering and Chief Technology Officer of NeuroMetrix Inc.

NeuroMetrix Inc. Reports Japan Regulatory Approval for NC-stat DPNCheck

NeuroMetrix Inc. reported the receipt of marketing certification from Technischer Überwachungs-Verein SÜD Japan Ltd. (TÜV SÜD Japan) for NC-stat DPNCheck as a Class II Designated Controlled Medical Device as defined in the technical standards of the Japan Ministry of Health, Labor, and Welfare. NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care test to detect diabetic peripheral neuropathy, or DPN, at an early stage allowing physicians to select appropriate treatment. DPN is the most common complication of diabetes, affecting over half of people with diabetes. DPN causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NURO:US $2.24 USD -0.01

NURO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Natus Medical Inc $24.92 USD +0.19
View Industry Companies

Industry Analysis


Industry Average

Valuation NURO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROMETRIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at